On-label on the table: What the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 11, 2012, Pages 1599-1613

  Citrome, Leslie ^a   Nasrallah, Henry A ^b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Atypical antipsychotic; FDA; Product label; Safety; Tolerability

Indexed keywords

ADRENALIN; ALCOHOL; ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; CAFFEINE; CARBAMAZEPINE; CIMETIDINE; CIPROFLOXACIN; CITALOPRAM; CLOZAPINE; DIAZEPAM; ERYTHROMYCIN; FLUOXETINE; FLUVOXAMINE; ILOPERIDONE; KETOCONAZOLE; LEVODOPA; LURASIDONE; OLANZAPINE; PALIPERIDONE; PAROXETINE; PHENYTOIN; QUETIAPINE; RANITIDINE; RIFAMPICIN; RISPERIDONE; UNINDEXED DRUG; VALPROATE SEMISODIUM; ZIPRASIDONE;

ABDOMINAL PAIN; ABNORMAL VISION; AGITATION; AKATHISIA; ANXIETY DISORDER; AREA UNDER THE CURVE; ASTHENIA; ATTRIBUTABLE RISK; BINDING AFFINITY; BLURRED VISION; BODY WEIGHT; CONSTIPATION; COUGHING; DECREASED APPETITE; DIZZINESS; DROWSINESS; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG INFORMATION; DRUG LABELING; DRUG MECHANISM; DRUG PACKAGING; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSARTHRIA; DYSPEPSIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERSALIVATION; HYPESTHESIA; HYPOTENSION; INCREASED APPETITE; INSOMNIA; IRRITABILITY DISORDER; LETHARGY; LIMB PAIN; MAJOR DEPRESSION; MANIA; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PERSONALITY DISORDER; PHARMACODYNAMICS; PHARYNGITIS; PRESCRIPTION; RESPIRATORY TRACT INFECTION; RESTLESSNESS; REVIEW; RHINITIS; RHINOPHARYNGITIS; RHINORRHEA; RIGIDITY; SALIVATION DISORDER; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SMOKING; SOMNOLENCE; SUICIDAL BEHAVIOR; SWEATING; SYNCOPE; TACHYCARDIA; THIRD TRIMESTER PREGNANCY; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT RESISTANT DEPRESSION; TREMOR; UPPER ABDOMINAL PAIN; VERTIGO; VISUAL DISORDER; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; DRUG LABELING; HUMANS; PRODUCT LABELING;

EID: 84863786453     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.626767     Document Type: Review

References (32)

1. Citrome L. Efficacy versus effectiveness. In: KATTAN MW, editor. Encyclopedia of Medical Decision Making. Sage Publications, Thousand Oaks, California, USA; 2009. p. 431-3
2. Citrome L. Evidence-based medicine: It's not just about the evidence. Int J Clin Pract 2011;65:634-5
3. Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: Heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother 2009;10:1917-28
4. US Food and Drug Administration. Structured Product Labeling Resources. Available from: Http://www.fda.gov/ForIndustry/DataStandards/ StructuredProductLabeling/default.htm [Last accessed 24 May]
5. US Food and Drug Administration. The FDA Announces New Prescription Drug Information Format. Last updated 2009 November 02. Available from: Http://www.fda.gov/Drugs/GuidanceComplianceRegulatory/Information/ LawsActsandRules/ucm188665.htm [Last accessed 24 May 2011]
6. Mitka M. Drug package inserts get mixed reception. JAMA 2006;295(10):1110-11
7. European Medicines Agency. Home Page. Available from: Http://www.ema. europa.eu/ema [Last accessed 24 May 2011]
8. Goodnick PJ. Higher than Physician's Desk Reference (US) doses on atypical antipsychotics. Expert Opin Drug Saf 2005;4:653-68
9. Steinmetz KL, Coley KC, Pollock BG. Assessment of geriatric information on the drug label for commonly prescribed drugs in older people. J Am Geriatr Soc 2005;53:891-4
10. De Leon J. Highlights of drug package inserts and the website DailyMed. The need for further improvement in package inserts to help busy prescribers. J Clin Psychopharmacol 2011;31:263-5
11. Novartis. Clozaril (clozapine). Revised December 2010. Available from: Http://www.pharma.us.novartis.com/product/pi/pdf/Clozaril.pdf [Last accessed 24 May 2011]
12. Janssen. Risperdal (risperidone). Revised April 2011. Available from: Http://www. risperdal.com/sites/default/files/shared/pi/risperdal.pdf [Last accessed 10 August 2011]
13. Eli Lilly. Zyprexa (olanzapine). Revised June 2011. Available from: Http://pi.lilly. com/us/zyprexa-pi.pdf [Last accessed 10 August 2011]
14. AstraZeneca. Seroquel (quetiapine). Revised July 2011. Available from: Http://www1.astrazeneca-us.com/pi/Seroquel.pdf [Last accessed 10 August 2011]
15. AstraZeneca. Seroquel XR (quetiapine extended release). Revised July 2011. Available from: Http://www1.astrazenecaus. com/pi/seroquelxr.pdf [Last accessed 10 August 2011]
16. Pfizer. Geodon (ziprasidone). Revised December 2010. Available from: Http://www.pfizer.com/files/products/uspi-geodon.pdf [Last accessed 10 August 2011]
17. Bristol-Myers Squibb. Abilify (aripiprazole). Revised February 2011. Available from: Http://www.abilify.com/pdf/pi.aspx [Last accessed 10 August 2011]
18. Janssen. Invega (paliperidone). Revised April 2011. Available from: Http://janssencns.com/sites/default/files/pdf/invega/invega.pdf [Last accessed 10 August 2011]
19. Novartis. Fanapt (iloperidone). Revised April 2011. Available from: Http://www. pharma.us.novartis.com/product/pi/pdf/fanapt.pdf [Last accessed 10 August 2011]
20. Merck. Saphris (asenapine). Revised October 2011. Available from: Http://www.spfiles.com/pisaphrisv1.pdf [Last accessed 7 October 2011]
21. Sunovion. Latuda (lurasidone). Revised October 2010. Available from: Http://www.latuda.com/LatudaPrescribingInformation.pdf [Last accessed 10 August 2011]
22. Eli Lilly. Symbyax (olanzapine and fluoxetine). Revised April 2011. Available from: Http://pi.lilly.com/us/symbyax-pi. pdf [Last accessed 10 August 2011]
23. US Food and Drug Administration. FDA Drug Safety Communication: Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns. 2011 February 22. Last updated 2011 March 29. Available from: http://www.fda.gov/Drugs/DrugSafety/ ucm243903.htm [Last accessed 27 May 2011]
24. Citrome L. Drug safety evaluation of ziprasidone. Expert Opin Drug Saf 2011;10:437-48
25. Citrome L. Iloperidone redux: A dissection of the Drug Approval Package for this newly commercialized second-generation antipsychotic. Int J Clin Pract 2010;64:707-18
26. Citrome L. Quantifying risk: The role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications. Curr Drug Saf 2009;4:229-37
27. Citrome L. Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: An analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Postgrad Med 2010;122:39-48
28. Edwards JG, Anderson I. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 1999;57:507-33
29. Mamah D, Wang L, Barch D, et al. Structural analysis of the basal ganglia in schizophrenia. Schizophr Res 2007;89:59-71
30. Scheepers FE, De Wied CC, Hulshoff Pol HE, et al. The effect of clozapine on caudate nucleus volume in schizophrenic patients previously treated with typical antipsychotics. Neuropsychopharmacology 2001;24:47-54
31. Brebion G, Bressan RA, Amador X, et al. Medications and verbal memory impairment in schizophrenia: The role of anticholinergic drugs. Psychol Med 2004;34:369-74
32. Shayegan DK, Stahl SM. Atypical antipsychotics: Matching receptor profile to individual patient's clinical profile. CNS Spectr 2004;9(Suppl 11):6-14